N′-(phenyl-2-yl-methylene)-hydrazine carbodithioic acid methyl ester enhances radiation-induced cell death by targeting Bcl-2 against human lung carcinoma cells

Molecular Cancer Therapeutics

Volumn 3, Issue 4, 2004, Pages 403-407

  Park, Jong Kuk ^a   Chung, Young Min ^a   Kim, Byung Gyu ^b   Yoo, Young A ^a   Yang, Beom Seok ^c   Kim, Jun Suk ^a   Yoo, Young Do ^a  

^a Korea University   (South Korea)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Korea Institute of Science and Technology   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

KETAMINE; MITOGEN ACTIVATED PROTEIN KINASE P38; N' (PHENYLPYRIDIN 2 YL METHYLENE)HYDRAZINECARBODITHIOIC ACID METHYL ESTER; PROTEIN BCL 2; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG; XYLAZINE; ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; GADD45A PROTEIN, HUMAN; GADD45A PROTEIN, MOUSE; HYDRAZONE DERIVATIVE; N' (PHENYLPYRIDIN 2 YLMETHYLENE)HYDRAZINE CARBODITHIOIC ACID METHYL ESTER; N'-(PHENYLPYRIDIN-2-YLMETHYLENE)HYDRAZINE CARBODITHIOIC ACID METHYL ESTER; NUCLEAR PROTEIN; PROTEIN BAX; PROTEIN P53; THIOCARBAMIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOASSAY; CANCER INHIBITION; CARCINOMA CELL; CELL DEATH; CONTROLLED STUDY; DOSIMETRY; DOWN REGULATION; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; INFRARED RADIATION; LUNG CARCINOMA; MALE; MOLECULAR LIBRARY; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT; ANIMAL; CELL DIVISION; CHEMISTRY; DRUG EFFECT; GAMMA RADIATION; LUNG NON SMALL CELL CANCER; METABOLISM; MOUSE; PHOSPHORYLATION; RADIATION EXPOSURE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; CELL DEATH; CELL DIVISION; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; GAMMA RAYS; HUMANS; HYDRAZONES; MICE; NUCLEAR PROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; RADIATION-SENSITIZING AGENTS; THIOCARBAMATES; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 4444334493     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin, 1999;49:8-31.
2. Kim JS, Amorino GP, Pyo H, Cao Q, Price JO, Choy H. The novel taxane analogs, BMS-184476 and BMS-188797, potentiate the effects of radiation therapy in vitro and in vivo against human lung cancer cells. Int J Radiat Oncol Biol Phys, 2001;51:525-34.
3. Palayoor ST, Bump EA, Calderwood SK, Bartol S, Coleman CN. Combined antitumor effect of radiation and ibuprofen in human prostate carcinoma cells. Clin Cancer Res, 1998;4:763-71.
4. Dicker AP, Williams TL, Grant DS. Targeting angiogenic processes by combination rofecoxib and ionizing radiation. Am J Clin Oncol, 2001;24: 438-42.
5. Kim KY, Seol JY, Jeon GA, Nam MJ. The combined treatment of aspirin and radiation induces apoptosis by the regulation of bcl-2 and caspase-3 in human cervical cancer cell. Cancer Lett, 2003;189:157-66.
6. Zhu AX, Willett CG. Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer. Semin Radiat Oncol, 2003;13:454-68.
7. Jones PD, de Lorimier LP, Kitchell BE, Losonsky JM. Gemcitabine as a radiosensitizer for nonresectable feline oral squamous cell carcinoma. J Am Anim Hosp Assoc, 2003;39:463-7.
8. Kondratov RV, Komarov PG, Becker Y, Ewenson A, Gudkov A. Small molecules that dramatically alter multidrug resistance phenotype by modulating the substrate specificity of P-glycoprotein. Proc Natl Acad Sci, 2001;98:14078-83.
9. Sohn TA, Su GH, Ryu B, Yeo CJ, Kern SE. High-throughput drug screening of the DPC4 tumor-suppressor pathway in human pancreatic cancer cells. Ann Surg, 2001;233:696-703.
10. Torrance CJ, Agrawal V, Vogelstein B, Kinzler KW. Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nat Biotechnol, 2001;19:940-5.
11. Heuer L, Kugler M, Paulus W, Lorentzen JP, Dehn HW, Erdelen C. Preparation of (pyridylmethyl) thiosemicarbazides as pesticides and industrial microbicides. Eur Pat Appl, 16.
12. 1 arrest in gastric cancer cells. Clin Cancer Res, 1998;4:3063-8.
13. Benhar M, Dalyot I, Engelberg D, Levitzki A. Enhanced ROS production in oncogenically transformed cells potentiates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to genotoxic stress. Mol Cell Biol, 2001;21:6913-26.
14. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science, 1995; 270:1326-31.
15. Liang Y, Jørgensen A, Kæstel CG, et al. Bcl-2, Bax, and c-Fos expression correlates to RPE cell apoptosis induced by UV-light and daunorubicin. Curr Eye Res, 2000;20:25-34.
16. Gudkov AV, Komarova EA. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer, 2003;3:117-29.
17. Tong T, Fan W, Zhao H, et al. Involvement of the MAP kinase pathways in induction of GADD45 following UV radiation. Exp Cell Res, 2001; 269:64-72.
18. Assefa Z, Garmyn M, Vantieghem A, et al. Ultraviolet B radiation-induced apoptosis in human keratinocytes: cytosolic activation of procaspase-8 and the role of Bcl-2. FEBS Lett, 2003;540:125-32.
19. Filippovich IV, Sorokina NI, Lisbona A, Cherel M, Chatal JF. Radiation-induced apoptosis in human myeloma cell line increases BCL-2/BAX dimer formation and does not result in BAX/BAX homodimerization. Int J Cancer, 2001;92:651-60.
20. Johnson MD, Xiang H, London S, et al. Evidence for involvement of Bax and p53, but not caspases, in radiation-induced cell death of cultured postnatal hippocampal neurons. J Neurosci Res, 1998;54:721-33.
21. Yu Y, Little JB. p53 is involved in but not required for ionizing radiation-induced caspase-3 activation and apoptosis in human lymphoblast cell lines. Cancer Res, 1998;58:4277-81.
22. Chernikova SB, Wells RL, Elkind MM. Wortmannin sensitizes mammalian cells to radiation by inhibiting the DNA-dependent protein kinase-mediated rejoining of double-strand breaks. Radiat Res, 1999;151: 159-66.
23. Edwards E, Geng L, Tan J, Onishko H, Donnelly E, Hallahan DE. Phosphatidylinositol 3-kinase/akt signaling in the response of vascular endothelium to ionizing radiation. Cancer Res, 2002;62:4671-7.
24. Eshleman JS, Carlson BL, Mladek AC, Kastner BD, Shide KL, Sarkaria JN. Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res, 2002;62: 7291-7.
25. Sarkaria JN, Tibbetts RS, Busby EC, Kennedy AP, Hill DE, Abraham RT. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res, 1998;58:4375-82.
26. 2 checkpoint abrogator. Cancer Res, 2001;61: 8211-7.
27. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer, 2002;2:647-56.
28. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res, 2001;61:3986-97.
29. Murakami I, Hiyama K, Ishioka S, Yamakido M, Kasagi F, Yokosaki Y. p53 gene mutations are associated with shortened survival in patients with advanced non-small cell lung cancer: an analysis of medically managed patients. Clin Cancer Res, 2000;6:526-30.
30. O'Byrne KJ, Koukourakis MI, Giatromanolaki A, et al. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor, and angiogenesis in non-small cell lung cancer. Br J Cancer, 2000;82: 1427-32.